| General Information | |
|---|---|
| ZINC ID | ZINC000028702490 |
| Molecular Weight (Da) | 478 |
| SMILES | CN[C@@H]1CCCC[C@H]1NC(=O)c1cn(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2Cl)n1 |
| Molecular Formula | C23Cl3N4O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 123.692 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 31 |
| LogP | 5.906 |
| Activity (Ki) in nM | 912.011 |
| Polar Surface Area (PSA) | 58.95 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.9078021 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.3 |
| Ilogp | 4.55 |
| Xlogp3 | 5.73 |
| Wlogp | 5.76 |
| Mlogp | 4.34 |
| Silicos-it log p | 4.99 |
| Consensus log p | 5.07 |
| Esol log s | -6.42 |
| Esol solubility (mg/ml) | 0.000181 |
| Esol solubility (mol/l) | 0.00000037 |
| Esol class | Poorly sol |
| Ali log s | -6.74 |
| Ali solubility (mg/ml) | 0.0000879 |
| Ali solubility (mol/l) | 0.00000018 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.78 |
| Silicos-it solubility (mg/ml) | 0.00000078 |
| Silicos-it solubility (mol/l) | 1.65E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.15 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.99 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.367 |
| Logd | 4.476 |
| Logp | 6.391 |
| F (20%) | 0.001 |
| F (30%) | 0.019 |
| Mdck | - |
| Ppb | 95.45% |
| Vdss | 1.429 |
| Fu | 2.41% |
| Cyp1a2-inh | 0.655 |
| Cyp1a2-sub | 0.665 |
| Cyp2c19-inh | 0.898 |
| Cyp2c19-sub | 0.175 |
| Cl | 2.519 |
| T12 | 0.028 |
| H-ht | 0.383 |
| Dili | 0.856 |
| Roa | 0.228 |
| Fdamdd | 0.952 |
| Skinsen | 0.064 |
| Ec | 0.003 |
| Ei | 0.005 |
| Respiratory | 0.401 |
| Bcf | 2.806 |
| Igc50 | 4.744 |
| Lc50 | 5.678 |
| Lc50dm | 5.44 |
| Nr-ar | 0.464 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.224 |
| Nr-aromatase | 0.059 |
| Nr-er | 0.184 |
| Nr-er-lbd | 0.004 |
| Nr-ppar-gamma | 0.007 |
| Sr-are | 0.152 |
| Sr-atad5 | 0.011 |
| Sr-hse | 0.011 |
| Sr-mmp | 0.557 |
| Sr-p53 | 0.727 |
| Vol | 446.821 |
| Dense | 1.066 |
| Flex | 0.25 |
| Nstereo | 2 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.491 |
| Synth | 3.202 |
| Fsp3 | 0.304 |
| Mce-18 | 78.2 |
| Natural product-likeness | -0.967 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |